Skip to content

Author

Yuan-Ming Xing

We have 2 of 22 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Aug 2026

Hepatic MED1 disruption ameliorates obesity-related fatty liver by attenuating SREBP1-driven lipogenesis.

BACKGROUND & AIMS Metabolic dysfunction-associated steatotic liver disease (MASLD) is a major global health concern, with obesity serving as a primary risk factor. Although Mediator subunit 1 (MED1) plays an important role in lipid metabolism, its specific contribution to obesity-related hepatic steatosis remains uncle...

Xu-Lei Dai, Zi-Yue Wang, Xiang-Zhu Xiao et al. · 0 citations
Open access Aug 2026

PCSK9 inhibitors for lipid-lowering treatment in patients with atherosclerotic cardiovascular disease: a health technology assessment

A health technology assessment framework is applied to systematically evaluate the use of PCSK9 inhibitors in patients with ASCVD and finds that evolocumab demonstrates relative advantages in lipid-lowering efficacy, cardiovascular outcomes, and economic value for patients with ASCVD.

Jing-Jing Lan, Yu-Lan Qiu, Shuaijian Wang et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.